Vitamin D and Kidney Diseases: A Narrative Review

Sahar Vahdat

Abstract


Vitamin D (Vit. D) is among the most important elements of the human body that play pivotal roles in health and disease. It belongs to the fat-soluble secosteroid family, which is provided by either foods or direct exposure to sunlight that converts 7-hydroxycholesterol to the Vit. D precursor. An alternative step is bio‑activation, which delivers an active form of Vit. D (Vit. D3), which participates in various noticeable functions including calcium regulation, bone remodeling, fertility, glucose control, and detoxification. The most recent literature is carefully reviewed (2049 articles) and the relative information was collected and discussed meticulously. Inclusion criteria were the articles that mentioned the relationship between Vit. D, adipokine, and kidney disease and exclusion criteria were nonrelevant articles. Vit. D plays several roles in the normal function of the kidney and metabolism. It has been revealed that Vit. D has a crucial impact on kidney disease and that its deficiency leads to kidney dysfunction and further renal disorder. Apart from the direct relationship of Vit. D with kidney disease, the association of adipocytes and adipokines with Vit. D and kidney function has also been studied. The noticeable role of Vit. D in kidney disease is investigated in various studies. It has been found that Vit. D has a pivotal role in kidney function and metabolism. Further study can reveal the better-detailed information about the exact relation of Vit. D and kidney disorders. The aim of the review was to provide a better insight into the exact role of Vit. D and adipokine in the kidney disease.

Keywords


Adipokine; chronic kidney disease; vitamin D

Full Text:

PDF

References


Brannon PM, Yetley EA, Bailey RL, Picciano MF. Overview of the conference “Vitamin D and health in the 21st century: An update”–. Am J Clin Nutr 2008;88:483S‑90S.2. Kulie T, Groff A, Redmer J, Hounshell J, Schrager S. Vitamin D: An evidence-based review. J Am Board Fam Med 2009;22:698‑706.3. Haussler MR, Whitfield GK, Kaneko I, Haussler CA, Hsieh D, Hsieh JC, et al. Molecular mechanisms of vitamin D action. Calcif Tissue Int 2013;92:77‑98.4. Bikle DD. Vitamin D metabolism, mechanism of action, and clinical applications. Chem Biol 2014;21:319‑295. Sequeira VB, Rybchyn MS, Tongkao‑On W, Gordon‑Thomson C, Malloy PJ, Nemere I, et al. The role of the vitamin D receptor and ERp57 in photoprotection by 1α, 25‑dihydroxyvitamin D3. Mol Endocrinol 2012;26:574‑826. Razzaque MS. The dualistic role of vitamin D in vascular calcifications. Kidney Int 2011;79:708‑14.7. Norman AW, Bouillon R. Vitamin D nutritional policy needs a vision for the future. Exp Biol Med (Maywood) 2010;235:1034‑45.8. Wang Y, Sun Z, Klotho gene delivery prevents the progression of spontaneous hypertension and renal damage. Hypertension 2009;54:810‑7.9. Segawa H, Aranami F, Kaneko I, Tomoe Y, Miyamoto K. The roles of Na/Pi‑II transporters in phosphate metabolism. Bone 2009;45:S2‑S7.10. Henry HL, Bouillon R, Norman AW, Gallagher JC, Lips P, Heaney RP, et al. 14th vitamin D workshop consensus on vitamin D nutritional guidelines. J Steroid Biochem Mol Biol 2010;121:4‑6.11. Choi HS, Oh HJ, Choi H, Choi WH, Kim JG, Kim KM, et al. Vitamin D insufficiency in Korea—a greater threat to younger generation: The Korea national health and nutrition examination survey (KNHANES) 2008. J Clin Endocrinol Metab 2011;96:643‑51.12. Hintzpeter B, Mensink GB, Thierfelder W, Müller MJ, Scheidt-Nave C. Vitamin D status and health correlates among German adults. Eur J Clin Nutr 2008;62:1079‑89.13. Rockell JE, Skeaff CM, Williams SM, Green TJ. Serum 25-hydroxyvitamin D concentrations of New Zealanders aged 15 years and older. Osteoporos Int 2006;17:1382‑9.14. Levin A, Bakris GL, Molitch M, Smulders M, Tian J, Williams LA, et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: Results of the study to evaluate early kidney disease. Kidney Int 2007;71:31‑8.15. Lee YM, Park SW, Kim JS, Wang JK, Kim JY, Park MS, et al. 25-Hydroxyvitamin D status in patients with chronic kidney disease in a single center. Korean J Nephrol 2010;29:458‑64.16. Wang WH, Chen LW, Lee CC, Sun CY, Shyu YC, Hsu HR, et al. Association between parathyroid hormone, 25 (OH) vitamin D, and chronic kidney disease: A population-based study. Biomed Res Int 2017; 2017:7435657.17. Ishimura E, Nishizawa Y, Inaba M, Matsumoto N, Emoto M, Kawagishi T, et al. Serum levels of 1, 25-dihydroxyvitamin D, 24, 25‑dihydroxyvitamin D, and 25‑hydroxyvitamin D in nondialyzed patients with chronic renal failure. Kidney Int 1999;55:1019‑27.18. Jean G, Souberbielle JC, Chazot C. Vitamin D in chronic kidney disease and dialysis patients. Nutrients 2017;9:328.19. Kim SM, Choi HJ, Lee JP, Kim DK, Oh YK, Kim YS, et al. Prevalence of vitamin D deficiency and effects of supplementation with cholecalciferol in patients with chronic kidney disease. J Ren Nutr 2014;24:20‑5.20. Kidney Disease: Improving Global Outcomes (KDIGO) CKD‑MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic kidney disease-mineral and bone disorder (CKD-MBD). Kidney Int Suppl 2009:S1‑130.21. Ravani P, Malberti F, Tripepi G, Pecchini P, Cutrupi S, Pizzini P, et al. Vitamin D levels and patient outcome in chronic kidney disease. Kidney Int 2009;75:88‑95.22. Kandula P, Dobre M, Schold JD, Schreiber MJ Jr, Mehrotra R, Navaneethan SD. Vitamin D supplementation in chronic kidney disease: A systematic review and meta-analysis of observational studies and randomized controlled trials. Clin J Am Soc Nephrol 2011;6:50‑62.23. Duranton F, Rodriguez‑Ortiz ME, Duny Y, Rodriguez M, Daurès JP, Argilés A. Vitamin D treatment and mortality in chronic kidney disease: A systematic review and meta-analysis. Am J Nephrol 2013;37:239‑48.24. Kovesdy CP, Ahmadzadeh S, Anderson JE, Kalantar‑Zadeh K. Association of activated vitamin D treatment and mortality in chronic kidney disease. Arch Intern Med 2008;168:397‑403.25. Drechsler C, Verduijn M, Pilz S, Dekker FW, Krediet RT, Ritz E, et al. Vitamin D status and clinical outcomes in incident dialysis patients: Results from the NECOSAD study. Nephrol Dial Transplant 2010;26:1024‑32.26. Teng M, Wolf M, Ofsthun MN, Lazarus JM, Hernán MA, Camargo CA Jr, et al. Activated injectable vitamin D and hemodialysis survival: A historical cohort study. J Am Soc Nephrol 2005;16:1115‑25.27. Filipov JJ, Zlatkov BK, Dimitrov EP, Svinarov D. Relationship between vitamin D status and immunosuppressive therapy in kidney transplant recipients. Biotechnol Biotechnol Equip 2015;29:331‑5.28. Ngai M, Lin V, Wong HC, Vathsala A, How P. Vitamin D status and its association with mineral and bone disorder in a multi-ethnic chronic kidney disease population. Clin Nephrol 2014;82:231‑9.29. Çankaya E, Bilen Y, Keleş M, Uyanık A, Akbaş M, Güngör A, et al. Comparison of serum vitamin D Levels among patients with chronic kidney disease, patients in dialysis, and renal transplant patients. Transplant Proc 2015;47:1405‑7.30. Kalantar‑Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, et al. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int 2006;70:771‑80.31. Naves‑Díaz M, Alvarez‑Hernández D, Passlick‑Deetjen J, Guinsburg A, Marelli C, Rodriguez‑Puyol D, et al. Oral active vitamin D is associated with improved survival in hemodialysis patients. Kidney Int 2008;74:1070‑8.32. Carrelli A, Bucovsky M, Horst R, Cremers S, Zhang C, Bessler M, et al. Vitamin D storage in adipose tissue of obese and normal weight women. J Bone Miner Res 2017;32:237‑42.33. Ding C, Gao D, Wilding J, Trayhurn P, Bing C. Vitamin D signalling in adipose tissue. Br J Nutr 2012;108:1915‑23.34. Li J, Byrne ME, Chang E, Jiang Y, Donkin SS, Buhman KK, et al. 1alpha, 25-Dihydroxyvitamin D hydroxylase in adipocytes. J Steroid Biochem Mol Biol 2008;112:122‑6.35. Ching S, Kashinkunti S, Niehaus MD, Zinser GM. Mammary adipocytes bioactivate 25-hydroxyvitamin D3 and signal via vitamin D3 receptor, modulating mammary epithelial cell growth. J Cell Biochem 2011;112:3393‑405.36. O’Hara A, Lim FL, Mazzatti DJ, Trayhurn P. Microarray analysis identifies matrix metalloproteinases (MMPs) as key genes whose expression is up-regulated in human adipocytes by macrophage‑conditioned medium. Pflugers Arch 2009;458:1103‑14.37. Trayhurn P, O’Hara A, Bing C. Interrogation of microarray datasets indicates that macrophage-secreted factors stimulate the expression of genes associated with vitamin D metabolism (VDR and CYP27B1) in human adipocytes. Adipobiology 2011;3:31‑6.38. Kamei Y, Kawada T, Kazuki R, Ono T, Kato S, Sugimoto E. Vitamin D receptor gene expression is up-regulated by 1, 25‑dihydroxyvitamin D3 in 3T3‑L1 preadipocytes. Biochem Biophys Res Commun 1993;193:948‑55.39. Kaneko I, Sabir MS, Dussik CM, Whitfield GK, Karrys A, Hsieh JC, et al. 1, 25-Dihydroxyvitamin D regulates expression of the tryptophan hydroxylase 2 and leptin genes: Implication for behavioral influences of vitamin D. FASEB J 2015;29:4023‑35.40. Wortsman J, Matsuoka LY, Chen TC, Lu Z, Holick MF. Decreased bioavailability of vitamin D in obesity. Am J Clin Nutr 2000;72:690‑3.41. Vimaleswaran KS, Berry DJ, Lu C, Tikkanen E, Pilz S, Hiraki LT, et al. Causal relationship between obesity and vitamin D status: Bi-directional mendelian randomization analysis of multiple cohorts. PLoS Med 2013;10:e1001383.42. Hotamisligil G. Inflammation and metabolic disorders. Nature 2006;444:860‑7.43. Huotari A, Herzig K‑H. Vitamin D and living in northern latitudes—An endemic risk area for vitamin D deficiency. Int J Circumpolar Health 2008;67:164‑78.44. Vlasova M, Purhonen AK, Jarvelin MR, Rodilla E, Pascual J, Herzig KH. Role of adipokines in obesity-associated hypertension. Acta Physiol (Oxf) 2010;200:107‑27.45. Kong J, Li YC. Molecular mechanism of 1, 25‑dihydroxyvitamin D3 inhibition of adipogenesis in 3T3‑L1 cells. Am J Physiol Endocrinol Metab 2006;290:E916‑24.46. Blumberg JM, Tzameli I, Astapova I, Lam FS, Flier JS, Hollenberg AN. Complex role of the vitamin D receptor and its ligand in adipogenesis in 3T3‑L1 cells. J Biol Chem 2006;281:11205‑13.47. Ross SE, Hemati N, Longo KA, Bennett CN, Lucas PC, Erickson RL, et al. Inhibition of adipogenesis by Wnt signaling. Science 2000;289:950‑3.48. Lee H, Bae S, Yoon Y. Anti‑adipogenic effects of 1, 25‑dihydroxyvitamin D3 are mediated by the maintenance of the wingless‑type MMTV integration site/β-catenin pathway. Int J Mol Med 2012;30:1219‑24.49. Cianferotti L, Demay MB. VDR‑mediated inhibition of DKK1 and SFRP2 suppresses adipogenic differentiation of murine bone marrow stromal cells. J Cell Biochem 2007;101:80‑8.50. Mahajan A, Stahl CH. Dihydroxy‑cholecalciferol stimulates adipocytic differentiation of porcine mesenchymal stem cells. J Nutr Biochem 2009;20:512‑20.51. Narvaez CJ, Simmons KM, Brunton J, Salinero A, Chittur SV, Welsh JE. Induction of STEAP4 correlates with 1, 25‑dihydroxyvitamin D3 stimulation of adipogenesis in mesenchymal progenitor cells derived from human adipose tissue. J Cell Physiol 2013;228:2024‑36.52. Trujillo ME, Scherer PE. Adipose tissue-derived factors: Impact on health and disease. Endocr Rev 2006;27:762‑78.53. Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004;89:2548‑56.54. Blüher M, Mantzoros CS. From leptin to other adipokines in health and disease: Facts and expectations at the beginning of the 21st century. Metabolism 2015;64:131‑45.55. Blüher M. Clinical relevance of adipokines. Diabetes Metab J 2012;36:317‑27.56. Parikh SJ, Edelman M, Uwaifo GI, Freedman RJ, Semega-Janneh M, Reynolds J, et al. The relationship between obesity and serum 1, 25-dihydroxy vitamin D concentrations in healthy adults. J Clin Endocrinol Metab 2004;89:1196‑9.57. Snijder MB, van Dam RM, Visser M, Deeg DJ, Dekker JM, Bouter LM, Adiposity in relation to vitamin D status and parathyroid hormone levels: A population-based study in older men and women. J Clin Endocrinol Metab 2005;90:4119‑23.58. Botella-Carretero JI, Alvarez-Blasco F, Villafruela JJ, Balsa JA, Vázquez C, Escobar‑Morreale HF. Vitamin D deficiency is associated with the metabolic syndrome in morbid obesity. Clin Nutr 2007;26:573‑80.59. Goldner WS, Stoner JA, Thompson J, Taylor K, Larson L, Erickson J, et al. Prevalence of vitamin D insufficiency and deficiency in morbidly obese patients: A comparison with non‑obese controls. Obes Surg 2008;18:145‑50.60. Blum M, Dolnikowski G, Seyoum E, Harris SS, Booth SL, Peterson J, et al. Vitamin D 3 in fat tissue. Endocrine 2008;33:90‑4.61. Wong KE, Kong J, Zhang W, Szeto FL, Ye H, Deb DK, et al.Targeted expression of human vitamin D receptor in adipocytes decreases energy expenditure and induces obesity in mice. J Biol Chem 2011;286:33804‑10.62. Fasshauer M, Blüher M. Adipokines in health and disease. Trends Pharmacol Sci 2015;36:461‑70.